申请人:AbbVie Inc.
公开号:US20130343993A1
公开(公告)日:2013-12-26
Compounds of formula (I) are disclosed
Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by 5-HT
6
receptor ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as 5-HT
6
positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
公式(I)的化合物已被披露。公式(I)的化合物在治疗由5-HT6受体配体预防或改善的疾病和疾病方面具有用途。公式(I)的放射标记化合物还可作为5-HT6正电子发射断层扫描配体的诊断工具。还披露了包括公式(I)化合物的药物组合物、使用这种化合物和组合物的方法,以及制备属于公式(I)范围内的化合物的过程。